IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological

Suzhou Ribo Life Science Co., Ltd. announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug development and AI-powered drug discovery to conduct in-depth collaboration in target discovery, drug molecule design and optimization, AI-assisted drug development and clinical translation. The two parties will advance the rollout of demonstration pro

ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficient drug discovery and development. As essential tools for innovative drug R&D, functional cell lines need clear, accessible usage authorization to keep projects on track. The updated policy expands authorized scope and eliminates redund

Delos Capital (“Delos”) and AP Biosciences, Inc. (“APBio”), today announced a strategic collaboration to create and incubate new biotechnology companies. The parties’ initial focus is the discovery and development of novel immune-related drug candidates through early clinical proof of concept. The model leverages Delos’ track record in building and leading biotech companies with APBio’s fully integrated R&D capabilities and operational e

Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE: IBM) have used IBM quantum computers and two of the world's most powerful supercomputers to simulate protein complexes spanning up to 12,635 atoms. These are the largest-known simulations of biologically meaningful molecules performed with quantum hardware yet, and signal that quantum computers are maturing into useful scientific tools which can help solve fundamental problems in biology, chemistry, and life sciences. The res

The 2026 HIMSS European Health Conference & Exhibition will bring together leading voices in digital health from 19–21 May, 2026, in Copenhagen, Denmark. As one of the premier gatherings for healthcare innovation, the event will spotlight world-class speakers and cutting-edge discussions addressing the most pressing challenges and opportunities across the healthcare ecosystem.

Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application to initiate a Phase 1b/ 2a clinical trial of CK0802 for the treatment of patients with steroid-refractory graft-versus-host disease (GVHD). Steroid-refractory GVHD represents a critical unmet need in post-transplant care. While allo

Dr. Reddy’s Laboratories Ltd. a global pharmaceutical company, today announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. Dr. Reddy’s becomes the first company to receive the market authorization for generic Semaglutide Injection* in Canada, ahead of Health Canada’s review target date. The market authorization covers the 2 mg / pen (1.34 mg / mL) and 4 mg / pen (1.34 mg / mL). With launch preparations underway,

Insilico Medicine a clinical-stage, generative AI–driven drug discovery company, today announced that the inhalation solution of Rentosertib (ISM001-055), the company's first-in-class drug candidate with AI-identified novel target and AI-developed molecule structure, received IND clearance from CDE. Notably, Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how Pharma.AI could reproducibly drive

Pfizer Inc. today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX® (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective U.S. patent expiry date for VYNDAMAX to June 1, 2031, subject to the outco